{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.8","upperLimit":"78.4","value":"71.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"}],"units":"Participants"}],"description":"CBR is defined as the percentage of participants who have achieved Complete Response (CR): Disappearance of all target lesions or Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \\[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm\\]) of ≥6 months per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-clear cell Renal Cell Carcinoma (nccRCC) received 400 mg Pembrolizumab (Pembro) intravenously (IV) on Day 1 of a 42-day cycle (every 6 weeks (Q6W)) for approximately 2 years PLUS 20 mg Lenvatinib (Lenva) orally once daily (QD) on Days 1 and 22 of a 42-day cycle (Q6W). Participants continued study intervention until progressive disease or discontinuation.","id":"OG000","title":"Pembrolizumab + Lenvatinib"}],"paramType":"NUMBER","populationDescription":"All allocated participants who received at least 1 dose of study intervention.","reportingStatus":"POSTED","timeFrame":"Up to approximately 47 months","title":"Clinical Benefit Rate (CBR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}